Research Article
[Retracted] Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines
Table 4
Results of cell cytotoxicity studies on different cell lines.
| | Samples | Percent viability | | MDA-MB231 | MCF7 | HEK 293 |
| | siRNA (50 nm) | 98.23 ± 0.22 | 95.43 ± 0.17 | 94.65 ± 0.32 | | C12 : DOTAP (1 : 1) | 78.27 ± 0.65 | 85.93 ± 0.33 | 90.31 ± 0.14 | | C12 : DOTAP:Chol (1 : 1 : 1) | 87.31 ± 0.15 | 88.69 ± 0.14 | 95.45 ± 0.24 | | C12 : Chol (1 : 1) | 81.26 ± 0.8 | 89.92 ± 0.15 | 91.14 ± 0.23 | | C12 : PEG (1 : 0.5) | 72.25 ± 0.42 | 93.62 ± 0.24 | 96.15 ± 0.15 | | C12 : PEG (1 : 0.5) + siRNA (50 nm) | 22.15 ± 0.55 | 30.59 ± 0.26 | 85.40 ± 0.30 | | C12 : Chol:DOT (1 : 1:1) + siRNA (50 nm) | 41.69 ± 0.32 | 47.84 ± 0.32 | 78.62 ± 0.25 | | C12 : DOT:(1 : 1) + siRNA (50 nm) | 48.25 ± 0.31 | 62.79 ± 0.11 | 80.24 ± 0.24 | | C12 : Chol (1 : 1) + siRNA (50 nm) | 55.92 ± 0.65 | 70.50 ± 0.14 | 82.25 ± 0.14 | | siRNA + lipofectamine 2000 | 60.32 ± 0.44 | 65.48 ± 0.22 | 68.64 ± 0.13 |
|
|
